Coronavirus vaccine candidate in China shows immune response, enters Phase 3 trial

A vaccine candidate against the novel coronavirus or SARS-Cov-2, developed by Sinopharm, has shown promising results in immune response trials, researchers claim. The vaccine candidate appears to be safe and have triggered antibody-based immune response in early and mid-stage trials and has now been moved to late-stage trials for regulatory approval, the Hindustan Times reported. As per a paper published by Sinopharm scientists and disease control authorities from China in the Journal of the American Medical Association, Phase 1 and 2 tests results from 320 healthy adults showed the candidate vaccine did not have any serious side effects. Sinopharm, a…